Chimerix, Exclusive Licensee of Cantex' Lead Product DSTAT, has Announced Initiation of a Phase 2/3 Study of DSTAT, Formerly Known as CX-01, in Acute Lung Injury for Patients with Severe COVID-19

• NASDAQ: $CMRX
• Notified: $1.94
• 08:42 EDT